Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Source: Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
In an engaging discussion led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Dr. Sara Hurvitz, MD, FACP, share how they currently use CDK4/6 inhibitors for their patients with metastatic HR-positive/HER2-negative breast cancer, the potential clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021, and strategies for counseling patients receiving CDK4/6 inhibitors.
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Released: August 19, 2021

Information on this Educational Activity

Faculty

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Women's Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Matthew P. Goetz, MD, has disclosed that he has received consulting fees paid to his institution from Biotheranostics, Biovica, Context Pharm, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer, and Sermonix and has received funds for research support paid to his institution from Lilly, Pfizer, and Sermonix.
Sara Hurvitz, MD, FACP

Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, and Zymeworks.
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received honoraria for consulting and/or advisory boards from AbbVie, Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Ondonate, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, and Syndax.

Program Medium

This program has been made available online.

Acknowledgements

Produced in collaboration with
Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.

Related Content

Laura M. Spring, MD, discusses the use of abemaciclib in patients with HR-positive, HER2-negative, node-positive early breast cancer, from Clinical Care Options (CCO)

Laura M. Spring, MD Released: November 29, 2021

person default Ashley Leak Bryant, PhD, RN, OCN, FAAN Sara Tinsley, PhD, APRN, AOCN Released: November 29, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue